Gary N. Schwartz MD

Contact Information:

Phone: (603) 653-6181

Fax: (603) 653-6191

Email: not given

Institution Affiliations:

Associate Professor of Medicine (Hematology/Oncology)

Department of: MEDICINE

Section: Hematology/Oncology

Specialty: Hematology/Oncology

Joined Staff: 2001

Cancer Center Membership:

Comprehensive Breast Oncology Program

Molecular Therapeutics Research Program

Breast Clinical Trials

Clinical Interests:

Breast Cancer

Board Certified:

Hematology/Oncology

Hematology 2000

Medical Oncology 1991 2000

Internal Medicine 1988

Degree(s): MD

Stanford University School of Medicine, Stanford, CA 1985

Internship(s):

Residency:

New York Hospital - Cornell Medical Center, New York, NY, (Internal Medicine) 1985-88

Fellowship(s):

Beth Israel Hospital, Boston, MA, (Hematology/Oncology) 1988-91

Biography:

In 1979 Dr. Schwartz received his BA from Stanford University and his MD in 1985 from Stansford. After completing an internal medicine residency in 1998 from New York Hospital, he did a three year h/o fellowship at the Beth Israel Hospital in Boston, MA. Dr. Schwartz then joined the faculty at Beth Israel from 1991 to 1995 and he left to become a Cancer Research Clinician at the Roswell Park Cancer Institute in Buffalo, NY. In the fall of 2000, Dr. Schwartz joined the DHMC H/O Section as an oncologist for the Breast Cancer Program.

Research Interests:

Dr. Schwartz research interests includes the study of chemoprotective agents and drug resistance and the development of Phase I trials.

Selected Publications:

Articles:

Ramnath N, Schwartz GN, Smith P, Bong D, Kanter P, Berdzik J, Creaven PJ. Phase I and pharmacokinetic study of anhydrovinblastine every 3 weeks in patients with refractory solid tumors. Cancer Chemother Pharmacol 2003, 51:227-230.

Pendyala L. Schwartz G. Smith P. Zdanowicz J. Murphy M. Hausheer F. Modulation of plasma thiols and mixed disulfides by BNP7787 in patients receiving paclitaxel/cisplatin therapy. Cancer Chemother Pharmacol 2003, 51(5):376-84.

Mulligan-Kehoe MJ, Schwartz GN, Zacharski LR. The functions of plasminogen activator inhibitor-1: do we have all the pieces of PAI? Thrombosis Research, in press, 2006.

Wells WA, Schwartz GN, Morganelli PM, Cole BF, Chambers JG, Kinlaw WB. Expression of "Spot 14" (THRSP) predicts disease free survival in invasive breast cancer: immunohistochemical analysis of a new molecular marker, Clinical Cancer Research, in press, 2006.

Abstracts:

Smith P, Booker B, Schwartz G, Kanter P, Berdzik J, Creaven P, Ramnath N. Pharmacokinetics/pharmacodynamics of anhydrovinblastine in a phase I clinical trial. Proc Am Soc Clin Oncol 2003; 22:576a.

Vinorelbine and trastuzumab enhance effector cell function in patients with HER-2/neu overexpressing metastatic breast cancer. Schwartz GN, Kaufman PA, Tretter CPG, Arrick BA, Mulrooney TJ, Connelly EM, Mellinger DL, Fisher JL, Ernstoff MS. Breast Cancer Research and Treatment 2004; 88 (Suppl 1):S128. Presented at San Antonio Breast Cancer Symposium, 2004.

Mailing Address:
Norris Cotton Cancer Center
Dartmouth-Hitchcock Medical Center
One Medical Center Drive
Lebanon, NH 03756